

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: License Agreement between the University of Michigan and Nanjing Novall Medical Co. Ltd

Action Requested: Approval of License Agreement

Preamble:

A statutory conflict of interest situation was identified by the Office of Technology Transfer while reviewing the technology transfer agreement that then triggered a review by the UMOR Conflict of Interest Review Committee. A plan for management of the possible risks associated with the conflict of interest was then developed and approved by this Committee and agreed to by the parties involved in this plan.

This proposed license agreement (“Agreement”) falls under the State of Michigan Conflict of Interest Statute because Dr. Yu Qin is an employee of the University of Michigan (“University”) and a partial owner of Nanjing Novall Medical Co. Ltd. The law permits such an Agreement provided it is disclosed to the Board of Regents (“Regents”) of the University of Michigan and approved in advance by a 2/3 vote.

Background:

Dr. Yu Qin, a Research Area Specialist Intermediate in the Department of Chemistry, is the partial owner of a for-profit company called Nanjing Novall Medical Co. Ltd (the “Company”). The Company was formed recently to commercialize nitric oxide releasing medical device technology and desires to license from the University of Michigan the University’s rights associated with the following technology:

UM OTT File No. 5584, entitled: “Polyurethanes Doped with S-Nitrosothiols for Nitric Oxide Release” (Inventors: Mark E. Meyerhoff, Elizabeth J. Brisbois, Hitesh Handa)

The Office of Technology Transfer selected the Company as a University partner and negotiated the terms of the proposed Agreement in accordance with University policy and its accepted licensing principles.

Parties to the Agreement:

The Regents of the University of Michigan and Nanjing Novall Medical Co. Ltd

Agreement Terms Include:

Agreement terms include granting the Company an exclusive license with the right to grant sublicenses in China and Hong Kong. The Company will pay a royalty on sales and reimburse patent costs. The University may receive equity in the Company, along with the right to purchase more equity.

The University will retain ownership of the licensed technology and may continue to further develop it and use it internally. No use of University services or facilities, nor any assignment of University employees, is obligated or contemplated under the Agreement. Standard disclaimers of warranties and indemnification apply, and the Agreement may be amended by consent of the parties, such as adding related technology. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Pecuniary Interest:

The pecuniary interests of Dr. Qin arise from his ownership interest in Nanjing Novall Medical Co. Ltd.

Net Effect:

The Office of Technology Transfer has negotiated and finalized the terms of a territory (China and Hongkong) exclusive license agreement for patents related to UM OTT File No. 5584 for all fields of use. Nanjing Novall Medical Co. Ltd will obtain use and commercialization rights to the above listed University technology.

Recommendations:

This matter has been reviewed and approved by the UMOR Conflict of Interest Review Committee. In light of this disclosure and our finding that the Agreement was negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the Agreement between the University and Nanjing Novall Medical Co. Ltd.

Respectfully submitted,



Rebecca Cunningham
Interim Vice President for Research

July 2019